The cell and gene therapy field is moving fast, and this eBook has been hand-picked to help you keep up with the latest developments.
Download the full eBook
We’ve pulled together some of the latest thinking, research, and tools shaping the future of this space. From AI-guided analysis and genome editing to cell reprogramming and advanced engineering, it’s a snapshot of how the field is shifting toward more precise, personalized treatments.
You’ll find practical insights into improving workflows, like better ways to engineer immune cells, new methods for in vivo editing, and smarter tools from synthetic biology and microbiology. There’s also a closer look at single-cell technologies, such as microfluidic droplet systems and high-throughput screening, which are helping teams obtain clearer and more reliable data.
Beyond the tech, the eBook also touches on where these therapies are headed in the real world, from cancer and regenerative medicine to neonatal care and biomaterials. Whether you're deep in R&D, working on clinical translation, or part of a growing biotech team, this collection provides a clear and useful view of where the field is headed and where the opportunities lie.
Grab your free copy of the eBook and see what has been shaping the field of cell and gene therapy.
Download the full eBook
About Fluidic Sciences and Sphere Bio
Fluidic Sciences develops transformative in‑solution technologies for protein interaction analysis. Its flagship Fluidity One‑M instrument leverages Microfluidic Diffusional Sizing (MDS) to measure binding affinity, stoichiometry, size, and concentration without immobilization - directly in complex backgrounds such as serum, plasma, and lysate.
Sphere Bio is a brand of Fluidic Sciences. Its technology develops and manufactures single‑cell analysis and monoclonality assurance systems that enable researchers to find, analyze, and isolate the most valuable cells with speed and precision. Its proprietary picodroplet microfluidics and Cyto‑Mine® Chroma multiplexing platform power applications across antibody discovery, cell line development, cell engineering, and cell therapy.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.